Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study

Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age

“…Many of these patients would not have been eligible for clinical trials due to, for example, poor PS (ECOG PS 2–4 40%) and/or comorbidities (CIRS‐G > 6 34%), and therefore, these findings are only available from this type of analysis. In comparison with recent population‐based analysis , our results present minimal missing data, especially in relation to the causes of death and progression events, which has enabled detailed analysis of the cumulative relapse risk.…”

Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines

“…Therefore, we used number of treatment cycles as a surrogate estimate for dose, assuming that each cycle contained 50 mg/m 2 doxorubicin. However, data from a recent Danish study including review of >1000 medical charts from elderly DLBCL patients have shown that dose reductions are common for elderly patients, with only 59% of 75‐ to 79‐year‐old patients scheduled for full dosing complete therapy without dose reductions and even fewer for those older than 79 years (Juul et al , ). Therefore, our study may underestimate the true dose‐response relationship between anthracyclines and cardiotoxicity.…”

Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B‐cell lymphoma: a Swedish lymphoma register study

“…For example, the dose‐reduced regimen R‐mini‐CHOP has demonstrated favourable efficacy as well as acceptable safety amongst patients aged ≥80, although this study excluded patients with a PS score >2, significant renal or liver disease or the presence of serious active disease, according to the investigator's decision, thus limiting the possibility to extrapolate this strategy to a comorbid population . However, concordant results were demonstrated in a population‐based study by Juul et al ., where patients aged ≥80 had a similar OS regardless of intended R‐CHOP doses, indicating that planned dose reductions are feasible amongst elderly and possibly comorbid patients. This is also in accordance with Eyre et al ., where preplanned dose reductions resulted in superior OS rates amongst patients aged >80.…”

“…We demonstrate that there is no increase in lymphoma‐specific mortality amongst comorbid patients treated with curative intent, including treatment with dose‐reduced regimens such as R‐mini‐CHOP. This is in line with the Danish population‐based study by Juul et al ., that included patients aged ≥75, which showed that standard treatment improved OS for all patients regardless of comorbidity up to age 80, and for patients aged >80 with CCI ≤ 2. Thus, standard treatment may be feasible and effective also for comorbid patients.…”